Back to results
US 2003/0225151 A1Published application
Pyrazole compositions useful as inhibitors of ERK
AssigneeVertex Pharmaceuticals Incorporated
InventorsMichael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang
Life of this patent
Estimating the term…
Abstract
Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1 where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
Claims24
A compound of formula I:
- 122
- or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
- R1 is selected from R, halogen, N(R8)2, OR, NRCOR, NRCON(R8)21, CON(R8)2, SO2R, NRSO2R, or SO2N(R8)2;
- T is selected from a valence bond or a linker group;
- each R is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons;
- R2 is selected from hydrogen, CN, halogen, aryl, aralkyl, heteroaryl, heterocyclyl, an optionally substituted acyclic aliphatic chain group having one to six carbons, or an optionally substituted cyclic aliphatic group having four to ten carbons;
- R3 is selected from R, OH, OR, N(R8)2, halogen, or CN;
- Q is a valence bond, J, or an optionally substituted C1-6 alkylidene chain wherein up to two nonadjacent carbons of the alkylidene chain are each optionally and independently replaced by J;
- J is selected from —C(═O)—, —CO2—, —C(O)C(O)—, —NRCONR8—, —N(R)N(R8)—, —C(═O)NR8—, —NRC(═O)—, —O—, —S—, —SO—, —SO2—, —N(R)O—, —ON(R8)—, —OC(═O)N(R8)—, —N(R)COO—, —SO2N(R8)—, —N(R)SO2—, or —N(R8)—;
- R4 is selected from —R8, —R5, —NH2, —NHR5, —N(R5)2, or —NR5(CH2)yN(R5) 2;
- each R5 is independently selected from R6, R7, —(CH2)yCH(R6)(R7), —(CH2)yR6, —(CH2)yCH(R6)2, —(CH2)yCH(R7)2, or —(CH2)yR7;
- y is 0-6;
- each R6 is an optionally substituted group independently selected from an aliphatic, aryl, aralkyl, aralkoxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, or heterocyclylalkoxy, group;
- each R7 is independently selected from an optionally substituted aliphatic, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, or alkoxycarbonyl;
- and
- each R8 is independently selected from R, or two R8 on the same nitrogen taken together with the nitrogen optionally form a four to eight membered, saturated or unsaturated heterocyclic ring having one to three heteroatoms;
- provided that QR4 is other than CON(CH3)2 when R1 and R3 are each hydrogen and when TR2 is an unsubstituted phenyl ring attached at the 4-position of the pyrazole ring.
14 more elements
Dependencies are inferred from the claim text.